NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
January 27, 2004 • Volume 1 / Number 4 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial


Clinical Trial Recruitment

Seeking Participants for New Clinical Trial in Rockville, Md.: Smoking Cessation for Cancer Survivors

Participants are needed for a study on quitting smoking in cancer survivors. All participants will receive the FDA-approved medication Zyban® along with one-on-one counseling. Cancer survivors may qualify if they:

  • Completed their cancer treatment at least six months ago;
  • Have been a regular smoker for at least two years;
  • Do not use smokeless tobacco, pipes, or cigars;
  • Are interested in quitting smoking; and
  • Are willing to take Zyban.

The study is being conducted at NCI's new Tobacco Intervention Research Clinic in Rockville, Md. For more information, call the clinic weekdays between 9:00 a.m. and 5:00 p.m. at 301-451-5048.

For more information on smoking cessation, please call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) or visit http://smokefree.gov.

For more information on smoking cessation in cancer survivors, please see http://www.cancer.gov/cancertopics/pdq/
supportivecare/smokingcessation/
. For more information on cancer clinical trials, go to http://www.cancer.gov/clinicaltrials.

Gefitinib for Non-Small Cell Lung Cancer Trial

Name of the Trial
Phase III Randomized Study of Adjuvant Gefitinib in Patients with Completely Resected Primary Stage IB, II, or IIIA Non-Small Cell Lung Cancer (CAN-NCIC-BR19). See the protocol summary at http://www.cancer.gov/clinicaltrials/CAN-NCIC-BR19.

Principal Investigators
Dr. Glenwood Goss of the National Cancer Institute of Canada; Dr. Gregory A. Masters of the Eastern Cooperative Oncology Group; and Dr. Peter Roberts of the Southwest Oncology Group.

Why Is This Trial Important?
Lung cancer is the second most common cancer and is the leading cause of cancer death in the United States. The more common type is non-small cell lung cancer, which grows slower than the more aggressive small cell lung cancer.

Biological therapies such as gefitinib (Iressa™) may interfere with and slow the growth of tumor cells. Furthermore, gefitinib, a targeted therapy, belongs to a new class of agents that generally have less severe side effects than those associated with traditional chemotherapy.

This study seeks to assess the effectiveness of gefitinib in prolonging the survival of patients who have undergone surgery for stage IB, II, or IIIA non-small cell lung cancer.

"We know from previous studies that chemotherapy can improve survival in patients with early-stage non-small cell lung cancer," said Dr. Goss. "What we seek to establish now is whether or not gefitinib can further improve the survival benefit, and do so with more tolerable side effects than one would experience with classic chemotherapy agents."

Who Can Join This Trial?
Researchers seek to enroll about 1,200 patients age 18 and older who have primary non-small cell lung cancer that has been surgically removed. See the full list of eligibility criteria for this trial at http://www.cancer.gov/clinicaltrials/CAN-NCIC-BR19.

Where Is This Trial Taking Place?
Multiple study sites in the United States, Canada, and elsewhere are enrolling patients in the gefitinib trial. See the list of study sites at http://www.cancer.gov/clinicaltrials/CAN-NCIC-BR19.

Who to Contact
See the list of study contacts at http://www.cancer.gov/clinicaltrials/CAN-NCIC-BR19 or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll-free and completely confidential.